Thrombosis pp 265-284 | Cite as

Influence of Antiplatelet Drugs on Platelet-Surface Interactions

  • Edwin W. Salzman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 102)

Abstract

Platelet aggregates are important in the thromboembolic complications of prosthetic devices, and drugs that alter platelet function have shown promise in clinical trials. Results with these drugs have increased insight into the interaction of platelets with artificial materials, particularly when the clinical experience has been correlated with the results of in vitro models.

In a bead column/surface contact model, the characteristic interactions of platelets with artificial surfaces resemble effects of adding thrombin or ADP to platelet-rich plasma. Anti-inflammatory agents and other antiplatelet drugs inhibit these reactions. Results in an in vivo model, survival of 51Cr-labeled platelets in sheep bearing arteriovenous shunts of test materials, correlate well with results in the in vitro model. Findings in these model systems indicate that the initial events upon contact of a surface with plasma proteins persistently influence the long-term behavior of that surface toward blood.

A review of clinical studies discusses the effect of antiplatelet drugs on platelet survival and also on thrombotic complications of heart valve replacement and other conditions employing prosthetic devices.

Keywords

Thromboembolic Complication Antiplatelet Drug Prosthetic Heart Valve Arteriovenous Shunt Prosthetic Device 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berger S, Salzman EW: Thromboembolic complications of prosthetic devices. In PROGRESS IN HEMOSTASIS AND THROMBOSIS, Vol. II, edited by Spaet TH. New York, Grune and Stratton, Inc., 1974, p. 273.Google Scholar
  2. 2.
    Salzman EW: Blood platelets: Their behavior with respect to extracorporeal membrane oxygenation. In ARTIFICIAL LUNGS FOR ACUTE RESPIRATORY FAILURE, edited by Zapol WM, Qvist J. Washington D.C., Hemisphere Corp., 1976, p. 105.Google Scholar
  3. 3.
    Salzman EW: Nonthrombogenic surfaces: Critical review. BLOOD 38: 509–523, 1971.PubMedGoogle Scholar
  4. 4.
    Mason RG: The interaction of blood hemostatic elements with artificial surfaces. In PROGRESS IN HEMOSTASIS AND THROMBOSIS, Vol. 1, edited by Spaet TH. New York, Grune and Stratton, 1972, p. 141.Google Scholar
  5. 5.
    Scarborough DE: The pathogenesis of thrombosis in artificial organs and vessels. CURR TOP PATHOL 54: 95, 1971.Google Scholar
  6. 6.
    Leonard EF, Friedman LI: Thrombogenesis on artificial surfaces: A flow reactor problem. CHEM ENG PROGR SYMP SER 66: 59–71, 1970.Google Scholar
  7. 7.
    Bruck SD (Ed): BLOOD COMPATIBLE SYNTHETIC POLYMERS: AN INTRODUCTION. Springfield, Mo., Charles C Thomas Publishers, 1974.Google Scholar
  8. 8.
    Verstraete M: Are agents affecting platelet functions clinically useful? AM J MED 61: 897–914, 1976.PubMedCrossRefGoogle Scholar
  9. 9.
    Genton E, Gent M, Hirsh J, Harker LA: Platelet-inhibiting drugs in the prevention of clinical thrombotic disease. N ENGL J MED 293:1174–1178, 1236–1240, 1296–1300, 1975.Google Scholar
  10. 10.
    Weiss HJ: Antiplatelet drugs–A new pharmacologic approach to the prevention of thrombosis. AM HEART J 92: 86–102, 1976.PubMedCrossRefGoogle Scholar
  11. 11.
    Salzman EW, Lindon J, Brier D, Merrill EW: Surface induced platelet adhesion, aggregation, and release. PROC NY ACAD SCI 283: 114–127, 1977.CrossRefGoogle Scholar
  12. 12.
    Salzman EW, Lindon JN, Rodvien R: Cyclic AMP in human blood platelets. Relation to platelet prostaglandin synthesis induced by centrifugation or surface contact. J CYCLIC NUCLEOTIDE RES 2: 25–37, 1976.PubMedGoogle Scholar
  13. 13.
    CazenaveJ-P, Packham MA, Guccione MA, Mustard JF: Inhibition of platelet adherence to a collagen-coated surface by non-steroidal anti-inflammatory drugs, pyrimido-pyrimidine and tricyclic compounds, and lidocaine. J LAB CLIN MED 83: 797–806, 1974.PubMedGoogle Scholar
  14. 14.
    Ali M, McDonald JWD: Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J LAB CLIN MED 89: 868–875, 1977.PubMedGoogle Scholar
  15. 15.
    Salzman EW: Cyclic AMP and platelet function. N ENGL J MED 286: 358–363, 1972.PubMedCrossRefGoogle Scholar
  16. 16.
    Salzman EW, Levine L: Cyclic 3’, 5’-adenosine monophosphate in human blood platelets: II. Effect of N6–2’-0-dibutyryl cyclic 3’, 5’-adenosine monophosphate on platelet function. J CLIN INVEST 50: 131–141, 1971.PubMedCrossRefGoogle Scholar
  17. 17.
    Wilner GD, Casarella WJ, Fenoglio C, Baier RE: In vivo fibrinopeptide a generation induced by angiographic catheters. THROMB HAEMOSTAS 38: 73, 1977.Google Scholar
  18. 18.
    Harker LA, Slichter SJ: Platelet and fibrinogen consumption in man. N ENGL J MED 287: 999–1005, 1972.PubMedCrossRefGoogle Scholar
  19. 19.
    Steele PP, Weily HS, Davies H, Genton E: Platelet function studies in coronary artery disease. CIRCULATION 48: 1194–1200, 1973.PubMedCrossRefGoogle Scholar
  20. 20.
    Steele PP, Weily HS, Genton E: Platelet survival and adhesiveness in recurrent venous thrombosis. N ENGL J MED 288: 1148–1152, 1973.PubMedCrossRefGoogle Scholar
  21. 21.
    Coe N, Collins R, Jagoda A, Brier D, Lindon J, Merrill E, Cohen R, Salzman E: In vivo assessment of thromboresistant materials by determination of platelet survival. THROMB HAEMOSTAS 38: 204, 1977.Google Scholar
  22. 22.
    Vroman L, Adams AL: Identification of rapid changes at plasmasolid interfaces. J BIOMED MATER RES 3: 43–67, 1969.PubMedCrossRefGoogle Scholar
  23. 23.
    Dutton RC, Webber AJ, Johnson SA, Baier RE: Microstructure of initial thrombus formation on foreign materials. J BIOMED MATER RES 3: 13–23, 1969.PubMedCrossRefGoogle Scholar
  24. 24.
    Lyman DJ, Brash JL, Chaikin SW, Klein KG, Carini M: Effect of chemical structure and surface properties of synthetic polymers on the coagulation of blood. II. Protein and platelet interaction with polymer surfaces. TRANS AM SOC ARTIF INTERN ORGANS 14: 250–255, 1968.PubMedGoogle Scholar
  25. 25.
    Scarborough DE, Mason RG, Dalldorf FG, Brinkhous KM: Morphological manifestations of blood-solid interfacial reactions. LAB INVEST 20: 164–169, 1969.PubMedGoogle Scholar
  26. 26.
    Packham MA, Evans G, Glynn MF, Mustard JF: Effect of plasma proteins on the interaction of platelets with glass surfaces. J LAB CLIN MED 73: 686–697, 1969.PubMedGoogle Scholar
  27. 27.
    Salzman EW, Merrill EW, Binder A, Wolf CF, Ashford TP, Austen WG: Protein-platelet interaction on heparinized surfaces. J BIOMED MATER RES 3: 69–81, 1969.PubMedCrossRefGoogle Scholar
  28. 28.
    Zucker MB, Vroman L: Platelet adhesion induced by fibrinogen adsorbed onto glass. PROC SOC EXP BIOL MED 131: 318–320, 1969.PubMedGoogle Scholar
  29. 29.
    Salzman EW: Thromboembolic complications of cardiac and vascular prostheses. In SURGERY OF THE CHEST, edited by Sabiston DC, Spencer FG. Philadelphia, W.B. Saunders Co., 1974, p. 1220.Google Scholar
  30. 30.
    Duvoisin GE, Brandenburg RO, McGoon DC: Factors affecting thromboembolism associated with prosthetic heart valves. CIRCULATION 35 (Suppl 1): 70–76, 1967.CrossRefGoogle Scholar
  31. 31.
    Sullivan JM, Harken DE, Gorlin R: Pharmacologic control of thromboembolic complications of cardiac valve replacement. N ENGL J MED 279: 576–580, 1968.PubMedCrossRefGoogle Scholar
  32. 32.
    Sullivan JM, Harken DE, Gorlin R: Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. CIRCULATION 39 (Suppl 1): 149, 1969.CrossRefGoogle Scholar
  33. 33.
    Stuart RK, McDonald JW, Ahuja SP, Coles JC: Platelet survival in patients with prosthetic heart valves. AM J CARDIOL 33: 840–844, 1974.PubMedCrossRefGoogle Scholar
  34. 34.
    Dale J, Myhre E, Storstein O, Stormorken H, Efskind L: Prevention of arterial thromboembolism with acetylsalicyclic acid. AM HEART J 94: 101–111, 1977.PubMedCrossRefGoogle Scholar
  35. 35.
    Altman R, Boullon F, Rouvíer J, Rada R, DeFuenta L, Favaloro R: Aspirin and prophylaxis of thromboembolic complications in patients with, substitute heart valves. J THORAC CARDIOVASC SURG 72: 127–129, 1976.PubMedGoogle Scholar
  36. 36.
    Taguchi K, Matsumura H, Washizu T, Hírao M, Kato K, Kato E, Mochizuki T, Takamura K, Mashimo I, Morifuji K, Nakagaki M, Suma T: Effect of athrombogenic therapy, especially high dose therapy dipyridamole, after prosthetic valve replacement. J CARDIOVASC SURG 16: 8–15, 1975.Google Scholar
  37. 37.
    Björk V, Henz A: Management of thrombo-embolism after aortic valve replacement with the Bjork-Shiley tilting disc valve. Medicamental prevention with dicumarol in comparison with dipyridamole–acetylsalicyclic acid. Surgical treatment of prosthetic thrombosis. SCAND J THORAC CARDIOVASC SURG 9: 183–191, 1975.PubMedCrossRefGoogle Scholar
  38. 38.
    Weily HS, Genton E: Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy. CIRCULATION 42 (Suppl 3): 205, 1970.Google Scholar
  39. 39.
    Weily HS, Steele PP, Davies H, Pappas G, Genton E: Platelet survival in patients with substitute heart valves. N ENGL J MED 290: 534–537, 1974.PubMedCrossRefGoogle Scholar
  40. 40.
    Steele P, Genton E: Thromboembolism and platelet survival time before and after valve surgery. ADV CARDIOL 17: 189–198, 1976.PubMedGoogle Scholar
  41. 41.
    Arrants JE, Hariston P, Lee WH, Jr.: Use of dipyridamole (persantine) in preventing thromboembolism following valve replacement. CHEST 58: 275, 1970.Google Scholar
  42. 42.
    Meyer JS, Charney JZ, Rivera VM, Mathew NT: Cerebral embolization: Prospective clinical analysis of 42 cases. STROKE 2: 541–554, 1971.PubMedCrossRefGoogle Scholar
  43. 43.
    Rabello C, Rivas JA, Rocha F et aZ.: Estudo da açâo de Dipiridamol na evoluçâo de pacientes submetiedos â substitui çao de prbteses valvares. REV BRAS CLIN TER 2: 95, 1973.Google Scholar
  44. 44.
    Moriau M, Ferrant A, Beys C, Hurlet A, Chalant C, Ponlot R, Jaumain P, Goenen M, Masure R: Evaluation of the antithrombotic properties of suloctidil in patients with substitute heart valves. THROMB HAEMOSTAS 38: 96, 1977.Google Scholar
  45. 45.
    Siegelman SS, Caplan LH, Annes GP: Complications of catheter angiography. Study with oscillometry and “pullout” angiograms. RADIOLOGY 91: 251–253, 1968.PubMedGoogle Scholar
  46. 46.
    Walker WJ, Mundall SL, Broderick HG, Prasad B, Kim J, Ravi JM: Systemic heparinization for femoral percutaneous coronary arteriography. N ENGL J MED 288: 826–828, 1973.PubMedCrossRefGoogle Scholar
  47. 47.
    Eyer KM: Complications of transfemoral coronary arteriography and their prevention using heparin. AM HEART J 86: 428, 1973.PubMedCrossRefGoogle Scholar
  48. 48.
    Hynes KM, Gau GT, Rutherford BD, Kazmier FJ, Frye RL: Effect of aspirin on brachial artery occlusion following brachial arteriotomy for coronary arteriography. CIRCULATION 47: 554–557, 1973.PubMedCrossRefGoogle Scholar
  49. 49.
    Freed MD, Rosenthal A, Fyler D: Attempts to reduce arterial thrombosis after cardiac catheterization in children: Use of percutaneous technique and aspirin. AM HEART J 87: 283–286, 1974.PubMedCrossRefGoogle Scholar
  50. 50.
    Jacobsson B: Use of dextran for prophylaxis against thromboembolic complication in arterial catheterization. ACTA CHIR SCAND (Suppl) 387: 103, 1968.Google Scholar
  51. 51.
    Evans G, Irvine WT: Long-term arterial-graft patency in relation to platelet adhesiveness, biochemical factors and anticoagulant therapy. LANCET 2: 353–355, 1966.PubMedCrossRefGoogle Scholar
  52. 52.
    Slichter SJ, Harker L, Sauvage L: Platelet consumption as a measure of endothelialization of aorta-femoral grafts. PROC AM SOC HEMATOL, Florida, 1972, p. 46.Google Scholar
  53. 53.
    Blakely JA, Pogoriler G: A prospective trial of sulfinpyrazone after peripheral vascular surgery. THRONE HAEMOSTAS 38: 238, 1977.Google Scholar
  54. 54.
    Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M: Arteriovenous-shunt thrombosis: Prevention by sulfinpyrazone. N ENGL J MED 290: 304–306, 1974.PubMedCrossRefGoogle Scholar
  55. 55.
    Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M: The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. CIRCULATION 52: 497–499, 1975.PubMedCrossRefGoogle Scholar
  56. 56.
    Andrassy K, Ritz E, Schoeffner W, Hahn G, Walter K: The influence of acetylsalicyclic acid on platelet adhesiveness and thrombotic fistula complications in hemodialysed patients. KLIN WOCHENSCHR 49: 166–167, 1971.PubMedCrossRefGoogle Scholar
  57. 57.
    Stuart M, Stockman J, Murphy S, Schut L, Ames M, Urmson J, Oski F: Shortened platelet lifespan in patients with hydrocephalus and ventriculojugular shunts: Results of preliminary attempts at correction. J PEDIATR 80: 21–25, 1972.PubMedCrossRefGoogle Scholar
  58. 58.
    Gralnick HR, Fischer RD: The hemostatic response to open-heart operations. J THORAC CARDIOVASC SURG 61: 909–915, 1971.PubMedGoogle Scholar
  59. 59.
    Heiden D, Mielke CH, Rodvien R, Hill JD: Platelets, hemostasis and thromboembolism during treatment of acute respiratory insufficiency with extracorporeal membrane oxygenation. J THORAC CARDIOVASC SURG 70: 644–655, 1975.PubMedGoogle Scholar
  60. 60.
    Backmann F, McKenna R, Cole ER, Najafi H: The hemostatic mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. J THORAC CARDIOVASC SURG 70: 76–85, 1975.Google Scholar
  61. 61.
    Bick RL: Alterations of hemostasis associated with cardiopulmonary bypass: Pathophysiology, prevention, diagnosis, and management. SEMIN THROMB HEMOSTAS 3: 59–82, 1976.Google Scholar
  62. 62.
    Harbury CB, Galvan CA: A bleeding diathesis associated with a platelet storage pool deficiency acquired during cardiopulmonary bypass surgery. THROMB HAEMOSTAS 38: 237, 1977.Google Scholar
  63. 63.
    Boyd AD, Engleman RM, Beaudet RL, Lackner H: Disseminated intravascular coagulation following extracorporeal circulation. J THORAC CARDIOVASC SURG 64: 685–693, 1972.PubMedGoogle Scholar
  64. 64.
    Allardyce DB, Yoshida SH, Ashmore PG: The importance of micro-embolism in the pathogenesis of organ dysfunction caused by prolonged use of the pump oxygenator. J THORAC CARDIOVASC SURG 52: 706–715, 1966.PubMedGoogle Scholar
  65. 65.
    Ashmore PG, Svitek V, Ambrose P: The incidence and effects of particulate aggregation and microembolism in pump-oxygenator systems. J THORAC CARDIOVASC SURG 55: 691–697, 1968.PubMedGoogle Scholar
  66. 66.
    Rittenhouse EA, Hessel EA, Ito CS, Merendino KA: Use of Persantin to reduce microaggregation in the pump oxygenator. SURG FORUM 21: 142–144, 1970.PubMedGoogle Scholar
  67. 67.
    Becker RM, Smith MR, Dobell ARC: Effect of dipyridamole on platelet function in cardiopulmonary bypass in pigs. SURG FORUM 23: 169, 1972.PubMedGoogle Scholar
  68. 68.
    Mielke CH, Hill JD, Geroode F: Drug influence on platelet loss during extracorporeal circulation. J THORAC CARDIOVASC SURG 66: 845–854, 1973.PubMedGoogle Scholar
  69. 69.
    Long DM, Todd DB, Indeglia RA, Varco RL, Lillehei CW: Clinical use of dextra-40 in extracorporeal circulation–A summary of 5 years’ experience. TRANSFUSION 6: 401–403, 1966.PubMedCrossRefGoogle Scholar
  70. 70.
    Bloom S, Zapol W, Wonders T, Berger S, Salzman E: Platelet destruction during 24 hour membrane lung perfusion. TRANS AM SOC ARTIF INTERN ORGANS 20: 299–305, 1974.Google Scholar
  71. 71.
    Winchester JF, Forbes CD, Courtney JM, Prentice CRM: Effect of sulfinpyrazone and aspirin on platelet loss induced in vitro by activated charcoal hemoperfusion. THROMB HAEMOSTAS 38: 93, 1977.Google Scholar
  72. 72.
    Lindsay RM, Prentice CRM, Kennedy AC, McNicol GP: Studies on thrombus formation and prevention within haemodialysers. BR J HAEMATOL 22: 640–641, 1972.PubMedGoogle Scholar
  73. 73.
    Lindsay RM, Prentice CRM, Ferguson D, Burton JA, McNichol GP: Reduction of thrombus formation of dialyser membranes by aspirin and RA 233. LANCET 2: 1287–1290, 1972.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1978

Authors and Affiliations

  • Edwin W. Salzman
    • 1
  1. 1.Department of SurgeryHarvard Medical School and Beth Israel HospitalBostonUSA

Personalised recommendations